British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis.

Neuro-Ophthalmology Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, PMR-GCA Scotland, Perth, Scotland, Department of Ophthalmology, King’s College Hospital, London, UK, Medical Centre for Rheumatology Berlin-Buch, Immanuel Hospital Berlin, Berlin, Germany, Rheumatology, Ipswich Hospital, Ipswich, UK, University of East Anglia, Ipswich, Rheumatology, Southend University NHS Foundation Trust, Westcliff-on-Sea, Essex, UK, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada, Department of

[1]  E. Matteson,et al.  Large‐Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease? , 2018, Arthritis care & research.

[2]  M. Tomšič,et al.  Does leflunomide have a role in giant cell arteritis? An open-label study , 2018, Clinical Rheumatology.

[3]  C. Juhl,et al.  2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis , 2018, Annals of the rheumatic diseases.

[4]  A. Scarsbrook,et al.  Comparative effectiveness of 18F-FDG PET-CT and contrast-enhanced CT in the diagnosis of suspected large-vessel vasculitis. , 2018, The British journal of radiology.

[5]  A. Iagnocco,et al.  Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group , 2018, RMD Open.

[6]  B. Bonnotte,et al.  Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. , 2018, Autoimmunity reviews.

[7]  J. Rizzo,et al.  Ophthalmic manifestations of giant cell arteritis. , 2018, Rheumatology.

[8]  Eric L Matteson,et al.  Large-vessel giant cell arteritis: diagnosis, monitoring and management , 2018, Rheumatology.

[9]  A. Iagnocco,et al.  EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice , 2018, Annals of the rheumatic diseases.

[10]  J. Stone,et al.  Trial of Tocilizumab in Giant‐Cell Arteritis , 2017, The New England journal of medicine.

[11]  H. Roschel,et al.  Exercise in Takayasu Arteritis: Effects on Inflammatory and Angiogenic Factors and Disease‐Related Symptoms , 2017, Arthritis care & research.

[12]  J. Krischer,et al.  A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis , 2017, Arthritis & rheumatology.

[13]  H. Bonel,et al.  Diagnostic value of contrast-enhanced magnetic resonance angiography in large-vessel vasculitis. , 2017, Swiss medical weekly.

[14]  G. Ioannidis,et al.  High‐Resolution Magnetic Resonance Imaging of Scalp Arteries for the Diagnosis of Giant Cell Arteritis: Results of a Prospective Cohort Study , 2017, Arthritis & rheumatology.

[15]  P. Merkel,et al.  The association of vascular risk factors with visual loss in giant cell arteritis , 2016, Rheumatology.

[16]  E. Matteson,et al.  The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease , 2016, Rheumatology.

[17]  M. Bradburn,et al.  The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. , 2016, Health technology assessment.

[18]  A. Zullo,et al.  Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression , 2016, BMC Medicine.

[19]  C. Turesson,et al.  The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis , 2016, BMC Musculoskeletal Disorders.

[20]  P. Dieudé,et al.  Positron emission tomography and computed tomography angiography for the diagnosis of giant cell arteritis , 2016, Medicine.

[21]  H. Bézanahary,et al.  Risk Factors for Permanent Visual Loss in Biopsy-proven Giant Cell Arteritis: A Study of 339 Patients , 2016, The Journal of Rheumatology.

[22]  S. Reichenbach,et al.  Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.

[23]  F. Galateau-Sallé,et al.  Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). , 2016, La Revue de medecine interne.

[24]  W. Dixon,et al.  Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force , 2016, Annals of the rheumatic diseases.

[25]  G. Haugeberg,et al.  The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? , 2016, Rheumatology.

[26]  K. Barraclough,et al.  2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative , 2015, Arthritis & rheumatology.

[27]  G. Guyatt,et al.  Guideline panels should not GRADE good practice statements. , 2015, Journal of clinical epidemiology.

[28]  G. Guyatt,et al.  Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients , 2015, BMJ : British Medical Journal.

[29]  V. Aboyans,et al.  [2014 ESC Guidelines on the diagnosis and treatment of aortic diseases]. , 2015, Kardiologia polska.

[30]  E. Matteson,et al.  Large-vessel giant cell arteritis: a cohort study. , 2015, Rheumatology.

[31]  B. Dasgupta,et al.  Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. , 2015, Clinical and experimental rheumatology.

[32]  M. Aschwanden,et al.  The ultrasound compression sign to diagnose temporal giant cell arteritis shows an excellent interobserver agreement. , 2015, Clinical and experimental rheumatology.

[33]  A. Hewitt,et al.  Projected Worldwide Disease Burden from Giant Cell Arteritis by 2050 , 2015, The Journal of Rheumatology.

[34]  T. Bley,et al.  3T MRI Reveals Extra- and Intracranial Involvement in Giant Cell Arteritis , 2015, American Journal of Neuroradiology.

[35]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[36]  N. Arden,et al.  The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. , 2015, Annals of the rheumatic diseases.

[37]  T. Bley,et al.  Giant cell arteritis: diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis-results from a multicenter trial. , 2014, Radiology.

[38]  A. Denniston,et al.  Aspirin as adjunctive treatment for giant cell arteritis. , 2014, The Cochrane database of systematic reviews.

[39]  M. Alba,et al.  Relapses in Patients With Giant Cell Arteritis , 2014, Medicine.

[40]  T. Kano,et al.  Large vessel vasculitis in elderly patients: early diagnosis and steroid-response evaluation with FDG-PET/CT and contrast-enhanced CT , 2014, Rheumatology International.

[41]  G. Haugeberg,et al.  Diagnostic Value of Color Doppler Ultrasonography of Temporal Arteries and Large Vessels in Giant Cell Arteritis: A Consecutive Case Series , 2014, Arthritis care & research.

[42]  G. Baron,et al.  Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial , 2013, Annals of the rheumatic diseases.

[43]  A. Morgan,et al.  Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis , 2012, Annals of the rheumatic diseases.

[44]  K. Chakravarty,et al.  BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. , 2014, Rheumatology.

[45]  V. Aboyans,et al.  [2014 ESC Guidelines on the diagnosis and treatment of aortic diseases]. , 2014, Kardiologia polska.

[46]  C. Strehl,et al.  Optimized glucocorticoid therapy: Teaching old drugs new tricks , 2013, Molecular and Cellular Endocrinology.

[47]  A. Diamantopoulos,et al.  Leflunomide as a Corticosteroid-Sparing Agent in Giant Cell Arteritis and Polymyalgia Rheumatica: A Case Series , 2013, BioMed research international.

[48]  D. Ray,et al.  EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases , 2013, Annals of the rheumatic diseases.

[49]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[50]  D. Wallace,et al.  An Inherited Heteroplasmic Mutation in Mitochondrial Gene COI in a Patient with Prostate Cancer Alters Reactive Oxygen, Reactive Nitrogen and Proliferation , 2012, BioMed research international.

[51]  S. Gabriel,et al.  Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis , 2012, Annals of the rheumatic diseases.

[52]  M. Aschwanden,et al.  Temporal Artery Compression Sign – A Novel Ultrasound Finding for the Diagnosis of Giant Cell Arteritis , 2012, Ultraschall in der Medizin.

[53]  M. Gonzalez-gay,et al.  Biopsy-proven giant cell arteritis patients with coronary artery disease have increased risk of aortic aneurysmal disease and arterial thrombosis. , 2013, Clinical and experimental rheumatology.

[54]  B. Dasgupta,et al.  Efficacy and tolerability of leflunomide in difficult‐to‐treat polymyalgia rheumatica and giant cell arteritis: a case series , 2012, International journal of clinical practice.

[55]  Marcelo Sánchez,et al.  Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography , 2012, Annals of the rheumatic diseases.

[56]  H. Habib,et al.  Color duplex ultrasonography of temporal arteries: role in diagnosis and follow-up of suspected cases of temporal arteritis , 2012, Clinical Rheumatology.

[57]  A. Morgan,et al.  Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. , 2011, Rheumatology.

[58]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[59]  Enrico Compalati,et al.  Application of GRADE: Making evidence-based recommendations about diagnostic tests in clinical practice guidelines , 2011, Implementation science : IS.

[60]  Howard Balshem,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[61]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[62]  J. Ioannidis,et al.  EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases , 2010, Annals of the rheumatic diseases.

[63]  D. Furst,et al.  American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis , 2010, Arthritis care & research.

[64]  K. Barraclough,et al.  BSR and BHPR guidelines for the management of giant cell arteritis. , 2010, Rheumatology.

[65]  M. Langer,et al.  Diagnostic value of T2‐weighted imaging for the detection of superficial cranial artery inflammation in giant cell arteritis , 2010, Journal of magnetic resonance imaging : JMRI.

[66]  K. Barraclough,et al.  BSR and BHPR guidelines for the management of polymyalgia rheumatica. , 2010, Rheumatology.

[67]  O. Steichen.  Comment on: Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. , 2009, Rheumatology.

[68]  G H Guyatt,et al.  Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies , 2009, Allergy.

[69]  D. Formisano,et al.  Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. , 2009, Rheumatology.

[70]  F. Buttgereit,et al.  Genomic and nongenomic effects of glucocorticoids , 2008, Nature Clinical Practice Rheumatology.

[71]  G. Hunder,et al.  Polymyalgia rheumatica and giant-cell arteritis , 2008, The Lancet.

[72]  M. Sonnenblick,et al.  Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. , 2008, Clinical and experimental rheumatology.

[73]  E. Mola,et al.  A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects , 2007, Annals of the rheumatic diseases.

[74]  S. Hayat.  Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis: A Randomized Trial , 2008 .

[75]  Andreas Krause,et al.  Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. , 2008, Rheumatology.

[76]  K. Chakravarty,et al.  BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. , 2007, Rheumatology.

[77]  Diagnostic Value of High-Resolution MR Imaging in Giant Cell Arteritis , 2007, American Journal of Neuroradiology.

[78]  P. Merkel,et al.  Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. , 2007, Arthritis and rheumatism.

[79]  Mahboob Rahman,et al.  Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis , 2007, Annals of Internal Medicine.

[80]  G. Hunder,et al.  Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. , 2006, Arthritis and rheumatism.

[81]  George Vaiopoulos,et al.  Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis , 2006, Arthritis research & therapy.

[82]  Jeffrey R Curtis,et al.  Population-based assessment of adverse events associated with long-term glucocorticoid use. , 2006, Arthritis and rheumatism.

[83]  L. Smeeth,et al.  Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001 , 2006, Annals of the rheumatic diseases.

[84]  J. Bratt,et al.  No additional steroid‐sparing effect of cyclosporine A in giant cell arteritis , 2006, Scandinavian journal of rheumatology.

[85]  M. Ramsay,et al.  Immunisation against infectious disease , 2006 .

[86]  M. Langer,et al.  Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. , 2005, Arthritis and rheumatism.

[87]  M. González-Gay,et al.  Influence of Traditional Risk Factors of Atherosclerosis in the Development of Severe Ischemic Complications in Giant Cell Arteritis , 2004, Medicine.

[88]  A. Romera-Villegas,et al.  The Role of Color Duplex Sonography in the Diagnosis of Giant Cell Arteritis , 2004, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[89]  G. Hunder,et al.  Aortic Aneurysm and Dissection in Patients With Biopsy-Proven Giant Cell Arteritis From Northwestern Spain: A Population-Based Study , 2004, Medicine.

[90]  D. Schmidt,et al.  Color-coded sonography in suspected temporal arteritis—experiences after 83 cases , 2004, Rheumatology International.

[91]  G. Hunder,et al.  Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. , 2003, Arthritis and rheumatism.

[92]  K. Pfadenhauer,et al.  Duplex sonography of the temporal and occipital artery in the diagnosis of temporal arteritis. A prospective study. , 2003, The Journal of rheumatology.

[93]  A. Evans,et al.  The use of ultrasound as an aid in the diagnosis of giant cell arteritis: a pilot study comparing histological features with ultrasound findings , 2003, Eye.

[94]  G. Meier,et al.  The utility of color duplex ultrasonography in the diagnosis of temporal arteritis. , 2002, Journal of vascular surgery.

[95]  R. Kardon,et al.  Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. , 2002, Acta ophthalmologica Scandinavica.

[96]  M. Sonnenblick,et al.  The predictive value of the halo sign in color Doppler ultrasonography of the temporal arteries for diagnosing giant cell arteritis. , 2002, The Journal of rheumatology.

[97]  K. Kalunian,et al.  A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. , 2002, Arthritis and rheumatism.

[98]  D. Sackett,et al.  The architecture of diagnostic research , 2002, BMJ : British Medical Journal.

[99]  G. Smetana,et al.  Does this patient have temporal arteritis? , 2002, JAMA.

[100]  M. Peterson,et al.  A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). , 2001, Clinical and experimental rheumatology.

[101]  E. Hachulla,et al.  Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. , 2001, Clinical and experimental rheumatology.

[102]  J. Jover,et al.  Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone , 2001, Annals of Internal Medicine.

[103]  C. Weyand,et al.  Pathogenic principles in giant cell arteritis , 2000, International journal of cardiology.

[104]  B. Grosbois,et al.  A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. , 2000, The Journal of rheumatology.

[105]  A. Maes,et al.  Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. , 2000, The American journal of medicine.

[106]  I. Yamada,et al.  Takayasu arteritis: evaluation of the thoracic aorta with CT angiography. , 1998, Radiology.

[107]  M. Delgado-Rodríguez,et al.  Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. , 1998, Arthritis and rheumatism.

[108]  E. Nordborg,et al.  No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. , 1998, British journal of rheumatology.

[109]  A. de la Sierra,et al.  Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. , 1998, Arthritis and rheumatism.

[110]  E. Gromnica-ihle,et al.  Color duplex ultrasonography in the diagnosis of temporal arteritis. , 1997, The New England journal of medicine.

[111]  E. Vidal,et al.  Does dapsone have a role in the treatment of temporal arteritis with regard to efficacy and toxicity? , 1993, Clinical and experimental rheumatology.

[112]  G. Hunder,et al.  Visual prognosis in giant cell arteritis. , 1993, Ophthalmology.

[113]  J. Lie.  Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. , 2010, Arthritis and rheumatism.

[114]  V. Kyle,et al.  Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. , 1989, Annals of the rheumatic diseases.

[115]  B. Hazleman,et al.  Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. , 1986, Annals of the rheumatic diseases.

[116]  J. Born,et al.  Influences of corticosteroids, dexamethasone and hydrocortisone on sleep in humans. , 1986, Neuropsychobiology.

[117]  G. Hunder,et al.  Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. , 1975, Annals of internal medicine.